- Home
- PDM vs SPRY Comparison
PDM vs SPRY Comparison
Compare PDM & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDM | SPRY |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 946.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PDM | SPRY |
|---|---|---|
| Price | $8.63 | $10.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $9.25 | ★ $31.25 |
| AVG Volume (30 Days) | 671.9K | ★ 2.2M |
| Earning Date | 10-27-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $565,372,000.00 | $142,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $124.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5459.66 |
| 52 Week Low | $5.46 | $6.66 |
| 52 Week High | $9.49 | $18.90 |
Technical Indicators
Market Signals| Indicator | PDM | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 59.12 |
| Support Level | $8.14 | $9.77 |
| Resistance Level | $8.85 | $11.45 |
| Average True Range (ATR) | 0.23 | 0.66 |
| MACD | 0.01 | 0.20 |
| Stochastic Oscillator | 61.90 | 71.26 |
Price Performance
Historical ComparisonAbout PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.